Compugen Ltd
CGEN - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$187.39M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $187.39 Million |
|---|---|
| Enterprise Value | $191.59 Million |
| Earnings per Share | $0.38 |
| Beta | 2.79 |
| Outstanding Shares | 94,640,696 |
Return
| Return on Equity | 39.66% |
|---|---|
| Return on Assets | 25.43% |
| Return on Invested Capital | 29.76% |
Valuation & Multiples
| P/E Ratio | 5.27 |
|---|---|
| PEG | -115.25 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 2.59 |
| Enterprise Value to EBIT | 5.56 |
| Enterprise Value to Net Income | 5 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | 0.16 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$-0.07
Consensus analyst estimateRevenue Estimate
$1.28 M
Consensus analyst estimateNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
$-0.08
Consensus analyst estimateRevenue Estimate
$1.28 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 144.22% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.17%▼ 13.79% |
|---|---|
| Total Invested | $2.63M▼ 91.32% |
| Investors Holding | 8▼ 79.00% |
About Compugen Ltd
75 employees
CEO: Anat Cohen-Dayag
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop therapeutics in the field of cancer immu...